Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05337345 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT05337345 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 104 participants.
The verdict
NCT05337345, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the drug levels of cendakimab delivered subcutaneously in healthy participants.
Interventions
- DRUG Cendakimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2022-05-02 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05337345
The ClinicalTrials.gov registry entry for NCT05337345 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cendakimab is the first listed.
NCT05337345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05337345 about?
NCT05337345 is a clinical study titled "A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants". The purpose of this study is to evaluate the drug levels of cendakimab delivered subcutaneously in healthy participants.
What is the current status of trial NCT05337345?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2022-05-02. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT05337345?
The interventions under investigation include: Cendakimab (DRUG).
Who is sponsoring clinical trial NCT05337345?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.